A YEAR IN REVIEW
ANNUAL REPORT FISCAL YEAR 2015
Welcome to the FY2015 JDRF Annual Report

Along with stories of success over the last fiscal year, you can click one of the icons below to explore extended content.

A Year in Review

Table of Contents

A Message from Our CEO and Chairman of the Board .............................................. 3
International Board of Directors and Chancellors .................................................... 4-5
One Voice Advocating for Special Diabetes Program Renewal ................................. 6-7
Leveraging Our Investments Toward a Bigger Payoff ............................................. 8-9
2015: The Year in Numbers ...................................................................................... 10-11
Moving the Artificial Pancreas to Market .............................................................. 12-13
Valued Partners in Our Fight for a Cure ................................................................. 14-15
A Message from Our CFO ..................................................................................... 16
FY2015 Condensed Financials ................................................................................. 17
Thank You to Our Supporters ................................................................................. 18-19

A Message from Our CEO and Chairman of the Board

Dear JDRF Community:

Our fiscal year 2015 Annual Report highlights the outstanding progress our organization made toward our mission of accelerating life-changing breakthroughs to cure, prevent and treat type 1 diabetes (T1D) and its complications. Each of you—our dedicated volunteers, supporters, partners and staff—was instrumental to the success of not only this past year but the many years of progress that laid the foundation for the exciting advances and opportunities we now see in the T1D research landscape.

JDRF’s commitment to alleviating the incredible burden of living with T1D until a cure becomes reality is as strong as ever. In the past year, JDRF affirmed our vision of a world without T1D, and we will not stop until that vision is realized.

We can’t do this alone. From our earliest days when a group of parents began to forge relationships with scientists, building and sustaining strong partnerships has been integral to our success. Through our collaborations with industry, governments, other research foundations and corporate partners, our influence and our impact grow exponentially.

In April, our tireless advocacy efforts helped secure a two-year renewal of the Special Diabetes Program, ensuring continued federal support for T1D research that would slow down or stop entirely without this funding.

In the following pages, you will read about some of the advances our collaboration and leadership have driven. Our job is far from done. We will push up on until TID is no longer a threat to anyone. We are grateful for this community of engaged and passionate supporters who believe as strongly in our vision of a world without T1D as we do.

Best regards,

Derek K. Rapp
JDRF, President & Chief Executive Officer

John Brady
JDRF, Chairman of the International Board of Directors

Thank you for your support and explain why they are committed to funding T1D research until we have a cure.

https://vimeo.com/146787596
International Board of Directors and Chancellors

JDRF leaders bring a vast range of professional knowledge and expertise to the governing of JDRF, but also share the common goal of creating a world without T1D for themselves and their loved ones.

JDRF INTERNATIONAL BOARD OF DIRECTORS

Diane Adams
Shannon Allen
Lisa Altman
Randy Anderson
Grant Beard
John Brady, Chairman of the Board
Karen Case, Chair, Finance
Tom Chapman, Chair, Nominating & Governance
Timothy Clark
Matthew Cohn
Rebecca Davies

JDRF CHANCELLORS

Fernando Aguirre
Dick Allen
Don Aron
Maureen Breen Barunas
Joan Beaubaire
Rik Bonness
Mary Elizabeth Bunzel

JDRF Chancellors (continued)

Terry Jackson
Andry Johnson
David W. Johnson
Larry King
Rik Kirkland
Robert Klein II
Anne Lacey
Ellen Leake
Jan Leeper
Stephen Leeper, D.D.S.
S. Robert Levine, M.D.
Richard Levy
James Liao, Esq.
Jim McDonald
John J. McDonough
Pat McFeeley
Steven M. Mardinger
Mollie Miller
Penny Moseley
Leah Mullen
Leo F. Mullin
George Nethercutt
Nettleton Payne II, M.D.
Penn Payne
Margery D. Perry
Gail Pressberg

Sandra Puczynski, Ph.D.
Charles J. Queenan III
Kenneth M. Rich
Mark Rubenstein
Steven Ruby, M.D.
Lewis R. Runnion
Pam Sagan, Chair, Chancellors
Robert Samuel
Helaine Shift
Sandra Silvestri
Adam Singer
Harold Smethills
Roy C. Smith
Emily Spitzer
Glen Tallman
Michael White
Peter A. Wilson
Bill Young, Jr.
Anne Zaring

SANDER STAFF

Derek K. Rapo, President & CEO
Richard A. Insel, M.D., Chief Scientific Officer
Aaron J. Kowalski, Ph.D., Chief Mission Officer & VP Research
Mark Greene, Chief Financial Officer & Assistant Treasurer
Gerri Feemster Bostick, SVP, Chief Human Resources Officer
Anne Bergquist, SVP, Marketing & Communications
Sandra Hjillkata, SVP, U.S. Field Development
Margo Lucero, SVP, Corporate & International Development
Cynthia Rice, SVP, Advocacy & Policy
Jill Clark, VP, Strategic Initiatives
Courtney Davies, VP, U.S. Field Operations
Emily Esklin, VP, Development Operations
Julia Greenstein, Ph.D., VP, Discovery Research
Steven Grifffen, M.D., VP, Translational Development
Gil King, VP, Internal Audit
John McGuire, CFRE, VP, Community Engagement, Peer-to-Peer Fundraising
Jit Patel, VP, Research Business Development
Patrick Reedy, VP, Leadership Giving
Linda C. Saulnier, VP, Donor Services
Sridhar Thodupunoori, VP, Information Technology
Nikki Bodnar, AVP, Digital & Creative Services
Sanjoy Dutta, Ph.D., AVP, Translational Development
Emily Milligan, AVP, Research
Sunil Notani, AVP, EPMO, Cloud & Big Data
Denz Satir, AVP, Signature Events
Robert Swanson, AVP, IT Operations

SENIOR STAFF

as of December 2015

JDRF ANNUAL REPORT FISCAL YEAR 2015

4

JDRF ANNUAL REPORT FISCAL YEAR 2015

5

JDRF ANNUAL REPORT FISCAL YEAR 2015

11
The passion and energy of JDRF Advocates are truly unmatched. In April 2015, JDRF celebrated a major policy success when Congress renewed the Special Diabetes Program (SDP) for a period of two years, through September 30, 2017. These two years will allow SDP-funded researchers at the National Institutes of Health (NIH), and at institutions around the country, to continue promising trials that are leading to better treatments, therapies and, ultimately—a cure for type 1 diabetes (T1D). Since the SDP was created, JDRF Advocates have demonstrated how grassroots efforts can be incredibly effective in advocating for the renewal of this important program. Our dedicated volunteers work around the clock to email, call and meet personally with Members of Congress and their staff to raise awareness of the financial, medical, and emotional costs of this serious disease.

Why Renewal of the SDP is Important
The reality is that without adequate funding for TID research, new developments cannot be made. To that end, Congress created the SDP in 1997 to address the growing burden of this disease by providing more money specifically for TID research. This critical program, which is currently fully funded at $150 million per year, has traditionally maintained broad bipartisan support across the aisle in Congress. The SDP has helped scientists make significant strides in TID cure therapies, prevention studies and treatments. Research supported by the SDP has accelerated progress in artificial pancreas technology, treatments for diabetic eye disease and beta cell biology. And, these are just some of the many examples of groundbreaking advances that the SDP has made possible.

Why Multiple-Year Funding is Essential
Since its inception, the SDP has generated nearly $2.5 billion—and it accounts for nearly 35 percent of all Federal Government funding for TID research. If the program is not renewed again prior to September 2017, this potentially life-saving research will slow down or could stop possibly entirely. Multiple-year funding renewal is essential because it allows scientists to continue large-scale trials, proactively plan next steps for research programs and allocate research dollars effectively. Not only is the SDP vitaly important for the future of TID research—it is also integral to JDRF’s mission to accelerate life-changing breakthroughs to cure, prevent and treat TID and its complications. That’s why JDRF Advocates will continue working tirelessly to educate both Congress, and the general public, on why the SDP must continue its efforts until we reach our goal. We won’t stop fighting until there is a cure for the millions of children and adults living with TID.

Lorraine Stiehl has been a valued member of the JDRF family for almost 30 years. Not only has she made a major impact in local, regional and national staff roles—Lorraine has also led our volunteer patient advocacy efforts, including the recent renewal of the Special Diabetis Program (SDP).

This success wouldn’t have been possible without JDRF’s phenomenal volunteer advocates, who build relationships with Members of Congress and educate them on how the research funded by the Special Diabetes Program is bringing us closer to a world without TID.

Cynthia Rice
JDRF Senior Vice President Advocacy & Policy
Lorraine helped illustrate the true power of volunteerism—including its role in successfully advocating for the renewal of the Special Diabetes Project (SDP) by Congress. Lorraine was also awarded National Volunteer of the Year in 2010 and she currently serves on the JDRF International Board of Directors.

Lorraine’s personal connection to T1D is her husband Chris, who was diagnosed at the age of 10—and has lived with the
disease for 56 years. For over half of his life, Chris didn’t have access to critical tools to help regulate his T1D. The turning point came when he received a continuous glucose monitor (CGM) at the age of 53, which provides him with real-time information on his blood sugar. Not only are the Stiehls passionate about ensuring that new therapies get the funding they need—they also support JDRF’s advocacy campaign to have CGMs covered by Medicare. And Lorraine credits
JDRF for helping to make life-changing treatments, like CGMs, possible. She says, “JDRF helped revolutionize T1D research—and care—which has enabled my husband to live a much fuller, longer life.”
Leveraging Our Investments Toward a Bigger Payoff

It takes a lot of resources to develop life-changing type 1 diabetes (T1D) therapies—resources that far surpass what JDRF is able to provide alone on our own. That’s where partnership, collaboration and influence come in.

A few years ago, JDRF developed a plan to bring more dollars and scientific talent to the T1D research arena by aggressively pursuing research-funding partnerships and leveraging our relationships and investment capital to encourage additional funding by other organizations. JDRF was successful in attracting nearly $100 million above and beyond our own investments in T1D research using this approach during fiscal year 2015. These leveraged investments came in the form of formal co-funding partnerships, collaborative agreements with other organizations to independently support specific research projects, and follow-on funding that researchers received as a result of successful work that was supported by JDRF. The attracted dollars came from industry, domestic and foreign governments, and other nonprofit entities.

JDRF’s recent work to invigorate the development of glucose responsive insulin (GRI) drugs highlights the promise and excitement of our leveraged-investment approach. In 2008, we began supporting work by the Massachusetts Institute of Technology (MIT) researcher Todd Zion, Ph.D., to establish preclinical proof of concept for an insulin drug that would turn on and off in response to changing blood-sugar levels and would require just one dose a day. The success of this work prompted the pharmaceutical company Merck to acquire and fund development of the resulting drug candidate. This achievement catalyzed other pharmaceutical companies to pursue GRI development, but a lack of innovative approaches for GRIs was limiting progress in the field.

JDRF’s commitment to the discovery and development of high-risk/high-reward research put us in a unique position to address these challenges. That’s why we set out to establish funding partnerships that would jump-start multiple GRI research projects. Our efforts resulted in a new $4.6 million partnership between JDRF and Sanofi, with each organization providing half of the funds. Four projects are being supported under the agreement, and the arrangement helps to ensure that promising research can continue advancing through the pipeline without delay. For example, JDRF used our academic research connections and understanding of innovation to solicit the most promising proposals for GRI discovery research, and we will help researchers troubleshoot problems as the projects progress. Sanofi is poised to move successfully developed GRI drug candidates through the translational and commercial development stages.

JDRF’s ability to create funding partnerships and attract follow-on funders is a direct reflection of the credibility, success and influence that we have established over more than four decades of work. By leveraging our relationships we are able to seed a greater number of innovative approaches to curing, preventing and better treating T1D.
In FY15, JDRF attracted nearly $100 million in additional partnership, collaborative and follow-on investments for research projects.

JDRF Committed
$27 million

Partners Committed Nearly
$100 million
JDRF’s long-standing partnership with the The Leona M. and Harry B. Helmsley Charitable Trust is an example of how JDRF’s collaborative agreements enable researchers to secure additional sources of funding. Through this ongoing relationship, JDRF and The Trust frequently confer about T1D therapeutic goals and agree to provide joint, coordinated support to projects in order to speed advancement towards new T1D therapies. JDRF and The Trust’s collaborative relationship has resulted in numerous coordinated funding arrangements over the past decade, including joint funding of BD Medical’s work to develop the FlowSmart technology infusion set, which experiences up to 80 percent less flow interruption.
RESEARCH FUNDING COMMITTED
2002 - 2022

For Every Dollar JDRF Invests Towards a Research Project...

JDRF dollars are the catalyst for other funders to invest millions of dollars as the research project aims are validated and the outcomes become less risky.
CO-FUNDING PARTNERSHIPS

Some of the most fruitful partnerships JDRF establishes are co-funding agreements with pharmaceutical and medical device companies. Through these agreements, each funder commits to providing a certain amount of money to support jointly solicited research projects over a specific period of time. One of the biggest advantages of these partnerships is that they not only provide sorely needed dollars to advance promising research, they also provide a continuum of expertise that helps drive projects through the discovery, product development and market delivery stages.
ACCELERATING PROGRESS IN FY15

COMMITTED $25.6M IN NEW FUNDING
AWARDED 121 NEW RESEARCH GRANTS
A TOTAL OF $72.4M WENT DIRECTLY TO T1D RESEARCH

FUGHTAINED 50 ACTIVE CLINICAL TRIALS
FUNDDED RESEARCH IN 18 COUNTRIES ACROSS THE GLOBE

UNITING THE T1D COMMUNITY

ALMOST 10,000 PEOPLE PARTICIPATED IN 30 TYPEONEATION SUMMITS ACROSS THE U.S.
12,000 BAGS OF HOPE AND 3,000 CARE KITS DELIVERED
96 LOCATIONS THROUGHOUT THE U.S.

T1D TODAY

1.25M AMERICANS HAVE T1D1,2,4
5M PEOPLE ARE EXPECTED TO HAVE T1D2,3

COMMITTED $25.6M IN NEW FUNDING
AWARDED 121 NEW RESEARCH GRANTS
A TOTAL OF $72.4M WENT DIRECTLY TO T1D RESEARCH

FUGHTAINED 50 ACTIVE CLINICAL TRIALS
FUNDDED RESEARCH IN 18 COUNTRIES ACROSS THE GLOBE

UNITING THE T1D COMMUNITY

ALMOST 10,000 PEOPLE PARTICIPATED IN 30 TYPEONEATION SUMMITS ACROSS THE U.S.
12,000 BAGS OF HOPE AND 3,000 CARE KITS DELIVERED
96 LOCATIONS THROUGHOUT THE U.S.

T1D TODAY

1.25M AMERICANS HAVE T1D1,2,4
5M PEOPLE ARE EXPECTED TO HAVE T1D2,3

COMMITTED $25.6M IN NEW FUNDING
AWARDED 121 NEW RESEARCH GRANTS
A TOTAL OF $72.4M WENT DIRECTLY TO T1D RESEARCH

FUGHTAINED 50 ACTIVE CLINICAL TRIALS
FUNDDED RESEARCH IN 18 COUNTRIES ACROSS THE GLOBE

UNITING THE T1D COMMUNITY

ALMOST 10,000 PEOPLE PARTICIPATED IN 30 TYPEONEATION SUMMITS ACROSS THE U.S.
12,000 BAGS OF HOPE AND 3,000 CARE KITS DELIVERED
96 LOCATIONS THROUGHOUT THE U.S.

T1D TODAY

1.25M AMERICANS HAVE T1D1,2,4
5M PEOPLE ARE EXPECTED TO HAVE T1D2,3

COMMITTED $25.6M IN NEW FUNDING
AWARDED 121 NEW RESEARCH GRANTS
A TOTAL OF $72.4M WENT DIRECTLY TO T1D RESEARCH

FUGHTAINED 50 ACTIVE CLINICAL TRIALS
FUNDDED RESEARCH IN 18 COUNTRIES ACROSS THE GLOBE

UNITING THE T1D COMMUNITY

ALMOST 10,000 PEOPLE PARTICIPATED IN 30 TYPEONEATION SUMMITS ACROSS THE U.S.
12,000 BAGS OF HOPE AND 3,000 CARE KITS DELIVERED
96 LOCATIONS THROUGHOUT THE U.S.

T1D TODAY

1.25M AMERICANS HAVE T1D1,2,4
5M PEOPLE ARE EXPECTED TO HAVE T1D2,3

COMMITTED $25.6M IN NEW FUNDING
AWARDED 121 NEW RESEARCH GRANTS
A TOTAL OF $72.4M WENT DIRECTLY TO T1D RESEARCH

FUGHTAINED 50 ACTIVE CLINICAL TRIALS
FUNDDED RESEARCH IN 18 COUNTRIES ACROSS THE GLOBE

UNITING THE T1D COMMUNITY

ALMOST 10,000 PEOPLE PARTICIPATED IN 30 TYPEONEATION SUMMITS ACROSS THE U.S.
12,000 BAGS OF HOPE AND 3,000 CARE KITS DELIVERED
96 LOCATIONS THROUGHOUT THE U.S.

T1D TODAY

1.25M AMERICANS HAVE T1D1,2,4
5M PEOPLE ARE EXPECTED TO HAVE T1D2,3

COMMITTED $25.6M IN NEW FUNDING
AWARDED 121 NEW RESEARCH GRANTS
A TOTAL OF $72.4M WENT DIRECTLY TO T1D RESEARCH

FUGHTAINED 50 ACTIVE CLINICAL TRIALS
FUNDDED RESEARCH IN 18 COUNTRIES ACROSS THE GLOBE

UNITING THE T1D COMMUNITY

ALMOST 10,000 PEOPLE PARTICIPATED IN 30 TYPEONEATION SUMMITS ACROSS THE U.S.
12,000 BAGS OF HOPE AND 3,000 CARE KITS DELIVERED
96 LOCATIONS THROUGHOUT THE U.S.

T1D TODAY

1.25M AMERICANS HAVE T1D1,2,4
5M PEOPLE ARE EXPECTED TO HAVE T1D2,3

COMMITTED $25.6M IN NEW FUNDING
AWARDED 121 NEW RESEARCH GRANTS
A TOTAL OF $72.4M WENT DIRECTLY TO T1D RESEARCH

FUGHTAINED 50 ACTIVE CLINICAL TRIALS
FUNDDED RESEARCH IN 18 COUNTRIES ACROSS THE GLOBE

UNITING THE T1D COMMUNITY

ALMOST 10,000 PEOPLE PARTICIPATED IN 30 TYPEONEATION SUMMITS ACROSS THE U.S.
12,000 BAGS OF HOPE AND 3,000 CARE KITS DELIVERED
96 LOCATIONS THROUGHOUT THE U.S.

T1D TODAY

1.25M AMERICANS HAVE T1D1,2,4
5M PEOPLE ARE EXPECTED TO HAVE T1D2,3

COMMITTED $25.6M IN NEW FUNDING
AWARDED 121 NEW RESEARCH GRANTS
A TOTAL OF $72.4M WENT DIRECTLY TO T1D RESEARCH

FUGHTAINED 50 ACTIVE CLINICAL TRIALS
FUNDDED RESEARCH IN 18 COUNTRIES ACROSS THE GLOBE

UNITING THE T1D COMMUNITY

ALMOST 10,000 PEOPLE PARTICIPATED IN 30 TYPEONEATION SUMMITS ACROSS THE U.S.
12,000 BAGS OF HOPE AND 3,000 CARE KITS DELIVERED
96 LOCATIONS THROUGHOUT THE U.S.

T1D TODAY

1.25M AMERICANS HAVE T1D1,2,4
5M PEOPLE ARE EXPECTED TO HAVE T1D2,3

COMMITTED $25.6M IN NEW FUNDING
AWARDED 121 NEW RESEARCH GRANTS
A TOTAL OF $72.4M WENT DIRECTLY TO T1D RESEARCH

FUGHTAINED 50 ACTIVE CLINICAL TRIALS
FUNDDED RESEARCH IN 18 COUNTRIES ACROSS THE GLOBE

UNITING THE T1D COMMUNITY

ALMOST 10,000 PEOPLE PARTICIPATED IN 30 TYPEONEATION SUMMITS ACROSS THE U.S.
12,000 BAGS OF HOPE AND 3,000 CARE KITS DELIVERED
96 LOCATIONS THROUGHOUT THE U.S.

T1D TODAY

1.25M AMERICANS HAVE T1D1,2,4
5M PEOPLE ARE EXPECTED TO HAVE T1D2,3

COMMITTED $25.6M IN NEW FUNDING
AWARDED 121 NEW RESEARCH GRANTS
A TOTAL OF $72.4M WENT DIRECTLY TO T1D RESEARCH

FUGHTAINED 50 ACTIVE CLINICAL TRIALS
FUNDDED RESEARCH IN 18 COUNTRIES ACROSS THE GLOBE

UNITING THE T1D COMMUNITY

ALMOST 10,000 PEOPLE PARTICIPATED IN 30 TYPEONEATION SUMMITS ACROSS THE U.S.
12,000 BAGS OF HOPE AND 3,000 CARE KITS DELIVERED
96 LOCATIONS THROUGHOUT THE U.S.

T1D TODAY

1.25M AMERICANS HAVE T1D1,2,4
5M PEOPLE ARE EXPECTED TO HAVE T1D2,3
Moving the Artificial Pancreas to Market

The University of Virginia’s (UVA) historic Charlottesville campus is home to an old four-bedroom gothic revival house that plays host to a special kind of slumber party. Sunnyside, as the house is known, is part of the UVA’s Center for Diabetes Technology. For the last decade, people with type 1 diabetes (T1D) have been going there to participate in overnight clinical trials of the Diabetes Assist (DiAs), an artificial pancreas (AP) system being developed by mathematician Boris Kovatchev, Ph.D., and his cross-disciplinary team of endocrinologists, psychologists, engineers and IT experts. The research that began at Sunnyside is now moving toward commercialization thanks, in large part, to early and continued support from JDRF.

AP systems are designed to automate glucose control and relieve the burden of finger sticks, carb counting and insulin injections. More importantly, AP systems will limit the time people with T1D spend outside of healthy blood-sugar range, helping them lessen the risk of long-term T1D complications such as diabetic eye disease, heart disease, kidney failure and diabetic amputations, as well as the constant threat of potentially deadly low-blood-sugar emergencies. JDRF has invested nearly $11.6 million in the work of Dr. Kovatchev’s team since 2006, including a grant of more than $2.6 million to support the latest clinical trial, which is the first to demonstrate that people with T1D can safely use AP systems in their daily lives for up to six consecutive months. During this free-living trial, participants were able to go about their daily routines wearing the DiAs system, which is composed of a control algorithm that is wirelessly connected to a continuous glucose monitor (CGM) and insulin pump. The algorithm receives data from the CGM and automatically instructs the pump to deliver precisely calibrated doses of insulin to keep the user’s blood glucose within healthy range. It wasn’t only JDRF direct funding that made the AP work being done at UVA possible. Our early funding helped UVA attract other funders—including the National Institutes of Health (NIH), the Helmsley Charitable Trust and EU AP@Home Project—who also saw value in the work.

It takes more than dollars, however, to get new therapies into the hands of people living with T1D. It also requires the expertise and dogged determination of people who can help build pathways for therapies like the one being developed by UVA to make it to market. In the case of AP technology, JDRF leadership played a crucial role beginning with the work of JDRF Chief Mission Officer Aaron Kowalski, Ph.D., to establish the Artificial Pancreas Project. The project is a far-reaching effort to create a roadmap towards U.S. Food and Drug Administration (FDA) approval of AP systems and bring together top researchers to advance AP technology. Equally as important is the work led by the JDRF Advocacy team to help ensure healthcare plans will ultimately cover these systems as they make it to market.

UVA’s most recent clinical trial, which wrapped in November 2015, lays the groundwork for commercialization. Members of the UVA team have formed TypeZero Technologies, a startup developing a suite of software products based on the DiAs system developed during UVA trials. TypeZero CEO Chad Rogers says the company is hoping to use one of two clinical trials slated to take place in early 2016 to acquire definitive safety and efficacy data that can be submitted to the FDA as a part of the premarket approval process.
insulin pump run by a control algorithm, to get her safely through the night. The algorithm processed data from the CGM and automatically instructed the pump to deliver precisely calibrated insulin doses as needed. The result: “blood-sugar levels of 100 straight across,” she says.

That outcome, which she calls “remarkable,” is especially significant to Melissa since her daughter also has T1D. “We are on alert 24 hours a day,” she says.
“When we go to bed, we’re waiting for the alarms on our pumps to go off. We are just exhausted, and sometimes I ask myself ‘how much longer can I do this?’” She says the most significant part of the trial was “the ability to take a break, even just at nighttime, even for just a week.” She’s looking forward to the AP system becoming commercially available in the near future, and thanks Dr. Kovatchev and his team for the work “that will completely change the lives of people with T1D.”
Valued Partners in Our Fight for a Cure

Ford Motor Company has been a valued partner of JDRF since 1983. In 1998, this unique relationship expanded when a vibrant employee-driven fundraising movement was created called the Ford Global Action Team (FGAT). This dedicated and committed team of volunteers brings together tens of thousands of Ford employees, their families, friends and business partners to support JDRF’s vision of creating a world without type 1 diabetes (T1D).

Under the leadership of Edsel B. Ford II, the FGAT has grown to more than 90 fundraising teams across 40 sites around the world. Thanks to the combined efforts of each team, the FGAT has raised more than $3 million annually for the past 14 years, which brings Ford’s total contribution to JDRF’s mission to more than $50 million.

JDRF Illinois Chapter’s partnership with the Ford Chicago Regional Office (CRO) FGAT team embodies the shared commitment to work together and leverage each other’s communities and resources to raise funds and awareness for T1D. CRO was a sponsor of the Ron Santo Walk to Cure Diabetes, and Ford employees enthusiastically raised extra funds through raffles, office cookouts and other creative initiatives. The Chicago FGAT team also worked closely with local Ford dealers in Illinois and Wisconsin to further establish the Dealer Family Walk Team Sponsorships. These sponsorships contributed $41,500 to CRO’s fundraising efforts, bringing their Walk fundraising total to more than $100,000.

In addition, Ford was the Live Auction Sponsor for JDRF’s 2014 One Dream Gala, and helped to raise $34,000 for the event. JDRF’s TypeOneNation outreach summits also benefited from Ford’s sponsorship, and a Winter Appeal campaign led by Ford raised nearly $40,000. In total, the Ford CRO raised more than $180,000 for JDRF in 2014 – the highest total since joining the FGAT in 2008.

The JDRF and Ford partnership stretches all the way to Australia, where both organizations embrace opportunities to collaborate and participate in fundraising events planned by JDRF and the FGAT.

The annual JDRF One Walk® in Melbourne brought the partners together with a strong team of Ford staff, family and friends participating to raise money. Ford hosted the popular 13th Annual Hot Rods and Hot Dogs fundraiser on the back lawn of Ford’s head office attracting hundreds of car enthusiasts and employees. More than 70 classic and muscle cars were on show, and the event helped to raise considerable funds and awareness for JDRF. In total, over $67,000 was raised in 2014 by the Melbourne FGAT.

Ford’s enormous global contribution to JDRF’s mission set a benchmark for how JDRF now engages with volunteers and partners. No other organization has so actively participated at a grassroots level by connecting their family and community networks with JDRF and the T1D community.

The 2015 Ford Race Car Design Contest for JDRF was an overwhelming success—raising close to $40,000 for T1D research.

I am so excited about winning this contest,” said Maryn, whose design raised $3,640 for JDRF. “I entered last year and couldn’t wait to design another car this year. This is awesome!”

Maryn Winters
8 years old, Basehor, KS

Click here to learn more.

*Figures are based on FGAT 2014 calendar year financials.
On January 17, 2015, the new Shelby GT350R, VIN #001 was auctioned off for $1,000,000 to an anonymous donor in Arizona at Barrett-Jackson Scottsdale.

Joining the Mustang on stage was Mark Fields, president and CEO of Ford Motor Company, JDRF CEO Derek Rapp and JDRF Youth Ambassadors.
Hosted by Motorcraft and Quick Lane, the contest allows children with T1D, ages 5 to 18, to create their own race car designs and then encourage others to vote by making a donation to their JDRF teams.

This year, 41 children entered the running to attend the 2015 NASCAR Sprint Cup race and see their design featured on the No. 21 Ford Fusion.

Maryn Winters, 8
Basehor, KS
On July 23, 2015, the champion—eight-year-old Maryn Winters—traveled to Indianapolis with her family for a once-in-a-lifetime experience.
A Message from Our CFO

To JDRF’s donors, fundraisers, and partners, we thank you for your continuing support that has led to JDRF funding more than $2 billion on type 1 diabetes (T1D) research, while also leveraging an additional $2 billion from industry, government, and foundations. Due to your leadership more money than ever before is being spent to fund research that will most quickly result in life-changing therapies and a cure for T1D.

This year, JDRF raised $200 million in public support with $186 million coming from the United States and an additional $14 million contributed by our international affiliates. From these funds, we have been able to put $145 million toward advancing T1D research efforts and supporting the community.

Several years ago, we accelerated the practice of tapping into our capital to benefit from once-in-a-generation opportunities to more rapidly advance progress in the most promising areas of T1D research. This allowed us to maximize opportunities to advance artificial pancreas technology toward commercialization, move encapsulated beta cell therapy research into human clinical trials and launch human trials of drugs with potential to regenerate beta cells.

More recently, we have been rebuilding that capital to ensure that we have the strong financial foundation required to get to the next level in our research priority fields and eventually create a world without T1D.

Mark Greene
Chief Financial Officer

FY2015 Condensed Financials

To view the FY15 financial statements which have been audited by KPMG LLP, please visit jdrf.org/financials
THANK YOU TO OUR SUPPORTERS

JDRF is the largest global funder of T1D research and it is because of our treasured supporters that we are able to continue to fund work that is impacting the lives of everyone living with this disease. Their passion, determination, energy and generosity push us to do more. Together, they are helping us achieve our vision of a world without T1D.

JDRF thanks all of our dedicated families, volunteers and local businesses who supported JDRF One Walk® and Walk to Cure Diabetes throughout FY2015. Your support is essential to JDRF’s fundraising strength and global growth.

We also express our deepest gratitude to our many corporate partners for their commitment and support of the JDRF Walk, both nationally and internationally.

With the support of our corporate partners, JDRF is able to increase the amount of research we fund. Our corporate partners encourage their employees to volunteer their time and engage their customers and vendors on our behalf. We thank each of our partners and their communities for their generosity and commitment in helping us turn Type One into Type None.

SPECIAL THANK YOU TO OUR FY2015 ELITE SPONSORS

Thank you to our elite sponsors who make it possible for JDRF to fund life-saving research and improve the lives of people living with T1D. Thank you:

- One Walk
- Walk to Cure Diabetes

Thank you to the riders who took part in the 2015 JDRF Ride to Cure Diabetes® season. With your support, the JDRF Ride continues to be one of our signature fundraising events.

Thank you to all the guests, supporters and volunteers who make each JDRF Gala successful and inspirational. We would like to extend a special thank you to all of the FY2015 Honorees who led their chapters in raising millions for JDRF.

The BETA Society includes people who have included JDRF as a beneficiary in their estate plans. We thank you for your planned-giving commitments to JDRF.